Arbutus Biopharma Corp. (ABUS)
4.09
+0.06
(+1.49%)
USD |
NASDAQ |
Nov 13, 16:00
4.095
0.00 (0.00%)
After-Hours: 19:59
Arbutus Biopharma Price : 4.09 for Nov. 13, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 13, 2026 | 4.04 | 4.135 | 3.92 | 4.09 | 3.311M |
| Nov 12, 2026 | 3.86 | 4.08 | 3.81 | 4.03 | 3.955M |
| Nov 11, 2026 | 3.82 | 3.90 | 3.65 | 3.88 | 2.130M |
| Nov 10, 2026 | 3.71 | 3.905 | 3.68 | 3.82 | 2.287M |
| Nov 09, 2026 | 3.68 | 3.75 | 3.59 | 3.72 | 1.709M |
| Nov 06, 2026 | 3.65 | 3.75 | 3.62 | 3.655 | 1.718M |
| Nov 05, 2026 | 4.02 | 4.055 | 3.615 | 3.67 | 6.160M |
| Nov 04, 2026 | 3.98 | 4.075 | 3.87 | 4.06 | 2.779M |
| Nov 03, 2026 | 4.01 | 4.055 | 3.87 | 3.88 | 2.386M |
| Nov 02, 2026 | 4.22 | 4.29 | 3.99 | 4.00 | 2.651M |
| Oct 30, 2026 | 4.28 | 4.304 | 4.141 | 4.21 | 2.526M |
| Oct 29, 2026 | 4.34 | 4.38 | 4.23 | 4.28 | 1.210M |
| Oct 28, 2026 | 4.24 | 4.33 | 4.22 | 4.32 | 1.343M |
| Oct 27, 2026 | 4.20 | 4.295 | 4.18 | 4.29 | 1.623M |
| Oct 26, 2026 | 4.22 | 4.26 | 4.18 | 4.20 | 1.405M |
| Oct 23, 2026 | 4.17 | 4.22 | 4.121 | 4.20 | 2.029M |
| Oct 22, 2026 | 4.22 | 4.37 | 4.175 | 4.21 | 2.464M |
| Oct 21, 2026 | 4.32 | 4.35 | 4.17 | 4.18 | 3.026M |
| Oct 20, 2026 | 4.24 | 4.365 | 4.22 | 4.33 | 2.114M |
| Oct 19, 2026 | 4.24 | 4.28 | 4.15 | 4.23 | 1.959M |
| Oct 16, 2026 | 4.29 | 4.29 | 4.18 | 4.22 | 4.542M |
| Oct 15, 2026 | 4.23 | 4.30 | 4.215 | 4.29 | 2.277M |
| Oct 14, 2026 | 4.07 | 4.25 | 4.05 | 4.19 | 2.434M |
| Oct 13, 2026 | 4.13 | 4.155 | 4.05 | 4.11 | 3.482M |
| Oct 12, 2026 | 4.20 | 4.23 | 4.12 | 4.15 | 2.343M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Gossamer Bio, Inc. | 10.97 |
| ACADIA Pharmaceuticals, Inc. | 18.75 |
| Alnylam Pharmaceuticals, Inc. | 165.04 |
| Anika Therapeutics, Inc. | 13.40 |
| Savara, Inc. | 4.64 |
Price Related Metrics
| PE Ratio | 3.652 |
| PS Ratio | 4.422 |
| Price to Book Value | 9.505 |
| Price to Free Cash Flow | 3.663 |
| Earnings Yield | 27.38% |
| Market Cap | 815.04M |
| Operating PE Ratio | 5.517 |
| Normalized PE Ratio | 3.673 |